Bright Minds Biosciences is a biotechnology company. Co. is creating chemical entities as targeted therapeutic agents for treatment of disorders where a serotonin (5-HT) receptor (either 5-HT2A, 5-HT2C or 5-HT2A/C) driven mechanism is the underlying pathology. These targeted neurocircuit disorders include neuropsychiatric, neurodegenerative, neuroinflammatory and pain disorders. Examples of these diseases include 5-HT2C disorders like pediatric epilepsies, Alzheimer's disease psychosis and dementia, 5-HT2A receptor disorders like depression and post-traumatic stress disorder, and 5-HT2A/C neuropathic pain syndromes including cluster headaches and chemotherapy induced peripheral neuropathy. The DRUG stock yearly return is shown above.
The yearly return on the DRUG stock yearly return page and across the coverage universe of our site,
is a measure of the annual return over the calendar year 2023 for the given stock.
When performing this calculation it is important to factor in dividends, because a financial instrument's annual return is
more than just the change in price if that instrument pays a dividend or coupon.
One way to factor dividends into the return is simply to count them as cash — we don't do
that here. Instead, our website aims to empower investors
by performing the DRUG annual return calculation with any dividends reinvested as applicable (on ex-dates).
|